Skip to content
High Tech Seed Founded 2018

BioSapien

Developer of 3D-printed drug delivery platforms for targeted pharmaceutical agents. The company focuses on creating minimally invasive methods for delivering medication directly. It utilizes its technology to provide drugs locally, avoiding negative systemic effects. The company's patented technology aims to transform patient care through innovative therapies. Founded in 2018, headquartered in New York City, United…

📍 New York City, United States · Nanotechnology,

Funding snapshot

Last roundSeed
Amount$2M
Date8 July 2025
Total raised$11M
Team size10

About

Developer of 3D-printed drug delivery platforms for targeted pharmaceutical agents. The company focuses on creating minimally invasive methods for delivering medication directly. It utilizes its technology to provide drugs locally, avoiding negative systemic effects. The company's patented technology aims to transform patient care through innovative therapies. Founded in 2018, headquartered in New York City, United States. The company has raised $10.6M in funding at the seed stage. BioSapien operates in the Nanotechnology, Drug Delivery sectors. The company focuses on Cancer Treatment, Patches. Notable investors include JPIN, SOSV, Hikma Ventures, Side Door Ventures, MicroVentures, DC Capital Ventures, among others. The company is categorized under High Tech > Nanotechnology; Life Sciences > Drug Delivery.

Business model

Nanotechnology > Nanoenabled Products > Life Science > Drug Delivery > Encapsulation > Cancer Treatment,

Drug Delivery > Patches

Institutional investors

JPIN SOSV Hikma Ventures Side Door Ventures MicroVentures DC Capital Ventures National Science Foundation Global Ventures DARA Holdings Golden Gate Ventures Hikma Pharmaceuticals Infinity Capital Ventures Beni Venture Capital Kartik Garg

Latest coverage

No articles yet.

Raising like BioSapien?

Analyze your pitch deck before your next raise.

Analyze My Deck →